| Sep 19 |
Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
|
| Sep 18 |
Jazz Pharmaceuticals' (NASDAQ:JAZZ) earnings have declined over five years, contributing to shareholders 16% loss
|
| Sep 16 |
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
|
| Sep 9 |
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
|
| Sep 8 |
Jazz Pharmaceuticals plc (JAZZ): Why Do Hedge Funds Recommend This Biotech Stock?
|
| Sep 5 |
Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
|
| Sep 5 |
Jazz Pharmaceuticals plc (JAZZ): Among the Best Mid-Cap Healthcare Stocks To Buy Now
|
| Sep 4 |
Jazz Pharmaceuticals prices $850M senior notes
|
| Sep 4 |
Jazz Pharmaceuticals Prices $850 Million Senior Notes Offering
|
| Sep 4 |
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
|
